The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma

NCT05868083 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Glioblastoma Multiforme

Interventions

DRUG: SNC-109 CAR-T Cells

Sponsor

Shanghai Simnova Biotechnology Co.,Ltd.

Collaborators

[object Object]